PubRank

Susan Cu-Uvin

Author PubWeight™ 83.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst 2003 2.81
2 Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin Infect Dis 2008 1.91
3 Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J Immunol 2002 1.76
4 Anti-HIV activity in cervical-vaginal secretions from HIV-positive and -negative women correlate with innate antimicrobial levels and IgG antibodies. PLoS One 2010 1.73
5 Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2003 1.71
6 Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 2003 1.57
7 The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol 2009 1.56
8 Bone disease and pathologic fractures in a patient with tenofovir-induced Fanconi syndrome. AIDS Read 2007 1.53
9 Antiretrovirals and safer conception for HIV-serodiscordant couples. Curr Opin HIV AIDS 2012 1.51
10 Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus-infected women in Western Kenya. J Low Genit Tract Dis 2012 1.50
11 Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr 2004 1.45
12 Trappin-2/Elafin: a novel innate anti-human immunodeficiency virus-1 molecule of the human female reproductive tract. Immunology 2009 1.37
13 Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis 2007 1.37
14 Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068. J Infect Dis 2006 1.37
15 High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol 2010 1.31
16 Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer 2006 1.28
17 Amplification of low-frequency antiviral CD8 T cell responses using autologous dendritic cells. AIDS 2002 1.27
18 Genital tract leukocytes and shedding of genital HIV type 1 RNA. Clin Infect Dis 2008 1.25
19 Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). Sex Transm Dis 2011 1.21
20 Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol 2006 1.20
21 Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 2005 1.17
22 Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol 2002 1.12
23 Discordance between spermatozoa detection and self-reported semen exposure. Sex Transm Dis 2011 1.11
24 Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet Gynecol 2006 1.06
25 HIV infection in refugees: a case-control analysis of refugees in Rhode Island. Int J Infect Dis 2008 1.03
26 Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics 2012 1.02
27 HIV and obstetric complications and fetal outcomes in Vellore, India. Trop Doct 2008 0.99
28 Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and Efavirenz. Infect Dis Obstet Gynecol 2012 0.98
29 Human immunodeficiency virus (HIV)-specific antibody in cervicovaginal lavage specimens obtained from women infected with HIV type 1. Clin Infect Dis 2002 0.97
30 T-lymphocyte profile and total and virus-specific immunoglobulin concentrations in the cervix of HIV-1-infected women. J Acquir Immune Defic Syndr 2007 0.97
31 Determinants of HIV shedding in the lower genital tract of women. Curr Infect Dis Rep 2008 0.97
32 Genital tract viral load in HIV Type 1-positive women correlates with specific cytokine levels in cervical-vaginal secretions but is not a determinant of infectious virus or anti-HIV activity. AIDS Res Hum Retroviruses 2012 0.96
33 Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR. Virol J 2010 0.94
34 The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 2002 0.93
35 Bacterial vaginosis and the natural history of human papillomavirus. Infect Dis Obstet Gynecol 2011 0.93
36 Effect of HIV infection on atypical squamous cells of undetermined significance. Clin Infect Dis 2006 0.92
37 Vaginal flora morphotypic profiles and assessment of bacterial vaginosis in women at risk for HIV infection. Infect Dis Obstet Gynecol 2005 0.92
38 Effect of treatment of asymptomatic bacterial vaginosis on HIV-1 shedding in the genital tract among women on antiretroviral therapy: a pilot study. Clin Infect Dis 2009 0.92
39 HIV and menopause: a review. J Womens Health (Larchmt) 2007 0.91
40 Effect of trichomoniasis therapy on genital HIV viral burden among African women. Sex Transm Dis 2012 0.89
41 Pregnancy-induced changes in immune protection of the genital tract: defining normal. Am J Obstet Gynecol 2013 0.89
42 The association between Trichomonas infection and incarceration in HIV-seropositive and at-risk HIV-seronegative women. Sex Transm Dis 2011 0.89
43 Pregnancy among HIV-infected refugees in Rhode Island. AIDS Care 2009 0.87
44 Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. Obstet Gynecol 2003 0.87
45 Genital tract interleukin-8 but not interleukin-1beta or interleukin-6 concentration is associated with bacterial vaginosis and its clearance in HIV-infected and HIV-uninfected women. Infect Dis Obstet Gynecol 2007 0.86
46 Prevalence and persistence of nonnucleoside reverse transcriptase inhibitor mutations in the female genital tract. J Acquir Immune Defic Syndr 2005 0.86
47 Selective impact of HIV disease progression on the innate immune system in the human female reproductive tract. PLoS One 2012 0.86
48 The menstrual cycle does not affect human immunodeficiency virus type 1 levels in vaginal secretions. J Infect Dis 2002 0.86
49 Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol 2007 0.85
50 Detection of fastidious vaginal bacteria in women with HIV infection and bacterial vaginosis. Infect Dis Obstet Gynecol 2009 0.85
51 Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 2005 0.85
52 The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. AIDS Patient Care STDS 2014 0.85
53 Substance use and psychotherapeutic medications: a likely contributor to menstrual disorders in women who are seropositive for human immunodeficiency virus. Am J Obstet Gynecol 2003 0.85
54 Nutritional biomarkers associated with gynecological conditions among US women with or at risk of HIV infection. Am J Clin Nutr 2007 0.85
55 Association between semen exposure and incident bacterial vaginosis. Infect Dis Obstet Gynecol 2011 0.85
56 In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women. Am J Obstet Gynecol 2012 0.84
57 Implications of blood contamination for assessment of local cellular immunity in the endocervix. AIDS Res Hum Retroviruses 2004 0.84
58 Changes in demographics and risk factors among persons living with HIV in an academic medical center from 2003-2007. Med Health R I 2009 0.83
59 Subtle perturbations of genital microflora alter mucosal immunity among low-risk pregnant women. Acta Obstet Gynecol Scand 2011 0.83
60 Assessing the relationship between cervical ectopy and HIV susceptibility: implications for HIV prevention in women. Am J Reprod Immunol 2012 0.82
61 See-and-treat approaches to cervical cancer prevention for HIV-infected women. Curr HIV/AIDS Rep 2011 0.82
62 Cervical intraepithelial neoplasia grade 2 or worse in human immunodeficiency virus-infected women with mildly abnormal cervical cytology. Obstet Gynecol 2008 0.81
63 Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2011 0.81
64 Accuracy of clinical diagnosis of bacterial vaginosis by human immunodeficiency virus infection status. Sex Transm Dis 2011 0.81
65 A pilot study of treatment of bacterial vaginosis with a buffering vaginal microbicide. J Womens Health (Larchmt) 2003 0.81
66 An Insight Into Cervical Cancer Screening and Treatment Capacity in Sub Saharan Africa. J Low Genit Tract Dis 2016 0.79
67 Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy. Clin Infect Dis 2013 0.79
68 HIV-2 diagnosis and quantification in high-risk patients. AIDS Res Ther 2008 0.79
69 Abnormal vaginal cytology in HIV-infected and at-risk women after hysterectomy. J Acquir Immune Defic Syndr 2004 0.79
70 Comparing Visual Inspection with Acetic Acid to Cytology in Detection of Precancerous Lesions of the Cervix in HIV-Infected Cambodian Women. J Int Assoc Physicians AIDS Care (Chic) 2011 0.78
71 Directly observed antiretroviral therapy to reduce genital tract and plasma HIV-1 RNA in women with poor adherence. AIDS 2003 0.78
72 Addition of Acyclovir does not affect Adherence to HAART in HIV-1/ HSV-2 Co-Infected Women. J AIDS Clin Res 2010 0.78
73 Special care issues of women living with HIV-AIDS. Infect Dis Clin North Am 2007 0.78
74 Clinical parameters essential to methodology and interpretation of mucosal responses. Am J Reprod Immunol 2011 0.78
75 Highly active antiretroviral therapy (HAART)--plus: next steps to enhance HAART in resource-limited areas? Clin Infect Dis 2007 0.78
76 The changing face of HIV in pregnancy in Rhode Island 2004-2009. Infect Dis Obstet Gynecol 2012 0.78
77 Use of visual inspection with acetic acid, Pap smear, or high-risk human papillomavirus testing in women living with HIV/AIDS for posttreatment cervical cancer screening: same tests, different priorities. AIDS 2017 0.78
78 Persistent genital tract HIV-1 RNA shedding after change in treatment regimens in antiretroviral-experienced women with detectable plasma viral load. J Womens Health (Larchmt) 2013 0.77
79 HIV and reproduction: fertility, contraception, and preconception issues and interventions. Infect Dis Obstet Gynecol 2012 0.77
80 Anatomic and hormonal changes in the female reproductive tract immune environment during the life cycle: implications for HIV/STI prevention research. Am J Reprod Immunol 2014 0.76
81 HIV-1 seroprevalence and awareness of mother-to-child transmission issues among women seeking antenatal care in Tamil Nadu, India. J Int Assoc Physicians AIDS Care (Chic) 2010 0.75
82 Use of VIA, Pap smear, or HR-HPV testing in women living with HIV/AIDS for post-treatment cervical cancer screening: same tests, different priorities. AIDS 2016 0.75
83 Antiretroviral-induced hepatotoxicity presenting as nonreassuring fetal testing. Obstet Gynecol 2010 0.75
84 Hepatocellular carcinoma in HIV-infected women: two case reports. R I Med J (2013) 2013 0.75
85 Special care issues of women living with HIV/AIDS. Med Health R I 2009 0.75
86 Pregnancy and optimal care of HIV-infected patients. Clin Infect Dis 2009 0.75